Autolus Therapeutics PLC has seen a significant increase in its stock price, rising by 11.29% following the announcement of the launch of AUCATZYL for the treatment of relapsed B-cell leukemia in the NHS. This new treatment option is expected to greatly enhance accessibility for patients in England and Wales, addressing an urgent need for innovative therapies in the biopharmaceutical market.
The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL for use in adult patients, which is a major step forward for Autolus. The approval is based on positive results from the FELIX study, which demonstrated the drug's efficacy in treating this challenging condition. This development not only strengthens Autolus's competitive position but also reflects the company's commitment to improving patient outcomes.
Investors are optimistic about the potential impact of AUCATZYL on Autolus's revenue and market share, as the company prepares for an imminent launch. The emphasis on patient involvement during the NICE evaluation process has also enhanced Autolus's reputation within the patient community, further solidifying its brand image.
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.430
Low
5.00
Averages
7.68
High
10.00
Current: 1.430
Low
5.00
Averages
7.68
High
10.00
Needham
Buy
maintain
$10 -> $11
2025-12-29
Reason
Needham
Price Target
$10 -> $11
AI Analysis
2025-12-29
maintain
Buy
Reason
Needham raised the firm's price target on Autolus Therapeutics to $11 from $10 and keeps a Buy rating on the shares. The firm also names Autolus a top pick for 2026. While Aucatzyl's launch has been impressive with $76M in sales, investors remain skeptical of Autolus, questioning if the company can reach breakeven, the analyst tells investors in a research note. Needham disagrees with skepticism, saying the shares offers an "attractive valuation" and a "strong opportunity for value creation in 2026." Data from the the FELIX study and obe-cel results in relapsed/refractory acute lymphoblastic leukemia indicate an expanding addressable market, contends the firm. Its modeling has Autolus reaching breakeven by 2028 based on Aucatzyl sales alone. Needham believes obe-cel in lupus nephritis receives little recognition at current share levels, which could change with clinical updates in the first half of 2026.
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Needham
Gil Blum
Price Target
$10
2025-04-10
Reiterates
Strong Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist Securities
Asthika Goonewardene
Price Target
$11 → $10
2025-04-01
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Wells Fargo
Yanan Zhu
Price Target
$8 → $6
2025-03-21
Maintains
Buy
Reason
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
